RemeGen Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REGMF research report →
About the company
RemeGen Co. , Ltd. , a biopharmaceutical firm established in Yantai, People's Republic of China, in 2008, focuses on the discovery, development, and commercialization of biologics.
- CEO
- Jianmin Fang
- IPO
- 2021
- Employees
- 2,999
- HQ
- Yantai, CN
Price Chart
- Market Cap
- $6.79B
- P/E
- 65.09
- P/S
- 24.29
- P/B
- 21.13
- EV/EBITDA
- 53.43
- Div Yield
- 0.00%
- Gross Margin
- 85.40%
- Op Margin
- 9.06%
- Net Margin
- 38.17%
- ROE
- 42.27%
- ROIC
- 5.01%
- Revenue
- $3.17B · 85.20%
- Net Income
- $690.24M · 147.01%
- EPS
- $1.26 · 146.15%
- Op Income
- $126.84M
- FCF YoY
- 90.28%
- 52W High
- $12.85
- 52W Low
- $5.06
- 50D MA
- $11.95
- 200D MA
- $10.53
- Beta
- 0.44
- Avg Volume
- 69
Get TickerSpark's AI analysis on REGMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our REGMF coverage
Recent articles, reports, and earnings notes.
No research on REGMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REGMF report →Similar companies
Peers in the same neighborhood.